A Phase 1, Open-Label, Randomized, Parallel Group Pilot Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Vedolizumab Administered in Prefilled Syringe Versus Prefilled Syringe in Needle Safety Device in Healthy Subjects
Latest Information Update: 19 Nov 2019
At a glance
- Drugs Vedolizumab (Primary)
- Indications Coeliac disease; Crohn's disease; Graft-versus-host disease; Malignant melanoma; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Takeda
- 17 May 2019 New trial record